The INF2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, designed to disrupt the INF2 gene. This product provides a heterogeneous pool of cells with targeted loss-of-function of INF2, enabling robust and reproducible studies that avoid clonal bottlenecks inherent in single-cell clones. The polyclonal format is particularly suited for experiments where population-level phenotypic effects are desired, offering a versatile model for exploring INF2-dependent cellular processes in cancer biology and beyond.
The host cell line, A-549, originates from a human lung adenocarcinoma and displays an epithelial, alveolar type II-like phenotype. Widely adopted as a model for non-small cell lung carcinoma, A-549 cells are adherent and maintain key characteristics of lung epithelial biology, including typical actin cytoskeletal organization and mitochondrial networks. Their relevance to lung adenocarcinoma research makes them an ideal background for investigating how INF2 disruption influences cell migration, invasion, and mitochondrial dynamics in a tumor-relevant context.
INF2, a member of the formin family, serves as a critical actin filament nucleation factor at endoplasmic reticulum (ER)-mitochondria contact sites. Its activity is modulated by upstream regulators such as RhoA, Cdc42, Rac1, and calcium influx. Functionally, INF2 promotes actin polymerization that physically constricts mitochondria, facilitating a DRP1-independent fission pathway by cooperating with Spire1 and interacting with IQGAP1 and myosin II. Downstream, INF2-mediated actin assembly influences DRP1 recruitment to mitochondria, focal adhesion dynamics, and overall mitochondrial morphology. The RhoA-INF2-Spire1-actin axis is a representative pathway, highlighting INF2’s integration of cytoskeletal and organelle dynamics.
In the context of A-549 cells, INF2 knockout offers a powerful tool to dissect the interplay between actin nucleation, mitochondrial fission, and lung cancer cell behavior. Since INF2 dysregulation is associated with focal segmental glomerulosclerosis (FSGS) and Charcot-Marie-Tooth disease with hearing loss, this model also permits cross-disease investigations. Specifically, it allows researchers to examine how loss of INF2 alters mitochondrial morphology, impairs regulated fission, and impacts ER stress responses and calcium signaling??processes that are often co-opted in adenocarcinoma malignancy and metastatic progression.
This INF2 knockout polyclonal cell population is amenable to a wide array of experimental applications. Immunofluorescence using phalloidin staining can reveal F-actin reorganization, while MitoTracker imaging enables detailed mitochondrial morphology analysis. Cell migration and invasion assays offer functional readouts relevant to cancer metastasis. Co-immunoprecipitation studies can probe INF2-Spire1 interactions, and western blotting or RT-qPCR can assess DRP1 phosphorylation and expression changes. The product is valuable for studying mitochondrial dynamics in cancer, modeling ER stress-associated actin polymerization, and investigating mechanisms of actin-related neuropathies. For further assistance and custom solutions, contact Ascent Research.
